EcoDrugPlus

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSONIG00000014781
Gene Symbol: CHRM2
4 Cross references
185 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSONIG00000020724
Gene Symbol: CHRM3
4 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSONIG00000008037
Gene Symbol: CHRM3
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSONIG00000021412
Gene Symbol: CHRM5
3 Cross references
189 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSONIG00000002702
Gene Symbol: CHRNA3
4 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSONIG00000006286
Gene Symbol: CHRNB2
4 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSONIG00000002699
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSONIG00000021029
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSONIG00000009364
Gene Symbol: CHRNA4B
1 Cross references
193 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSONIG00000016111
Gene Symbol: F2R
1 Cross references
215 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSONIG00000015444
Gene Symbol: F2R
4 Cross references
249 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSONIG00000015442
Gene Symbol: F2R
4 Cross references
248 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).